









Markets
/
Stocks
/
nasdaq-cprx
/

Catalyst Pharmaceuticals Inc

CPRX

24.440USD

+0.530+2.22%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

3.01BMarket Cap

13.64P/E TTM



Catalyst Pharmaceuticals Inc

24.440

+0.530+2.22%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Catalyst Pharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

Catalyst Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 5 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 34.50.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Catalyst Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

5 / 159

Overall Ranking

22 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Catalyst Pharmaceuticals Inc Highlights

StrengthsRisks

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 129.56% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 491.73M.

Fairly Valued

The company’s latest PE is 13.64, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 106.95M shares, increasing 0.01% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 1.10M shares of this stock.

Analyst Rating

Based on 8 analysts

Strong Buy

Current Rating

34.500

Target Price

+44.29%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Catalyst Pharmaceuticals Inc is 9.12, ranking 16 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 148.39M, representing a year-over-year increase of 15.31%, while its net profit experienced a year-over-year increase of 20.28%.

Score

Industry at a Glance

Previous score

9.12

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.83

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.78

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Catalyst Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Catalyst Pharmaceuticals Inc is 7.97, ranking 36 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 13.64, which is 169.27% below the recent high of 36.72 and 22.08% above the recent low of 10.62.

Score

Industry at a Glance

Previous score

7.97

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 5/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Catalyst Pharmaceuticals Inc is 9.25, ranking 3 out of 159 in the Pharmaceuticals industry. The average price target is 34.00, with a high of 40.00 and a low of 32.00.

Score

Industry at a Glance

Previous score

9.25

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Strong Buy

Current Rating

34.500

Target Price

+44.29%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Catalyst Pharmaceuticals Inc

CPRX

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Catalyst Pharmaceuticals Inc is 9.09, ranking 40 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 25.94 and the support level at 22.54, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.51

Change

1.58

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.092

Buy

RSI(14)

54.587

Neutral

STOCH(KDJ)(9,3,3)

44.385

Sell

ATR(14)

0.846

Low Volatility

CCI(14)

-4.733

Neutral

Williams %R

34.062

Buy

TRIX(12,20)

0.256

Sell

StochRSI(14)

31.000

Neutral

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

24.726

Sell

MA10

24.477

Sell

MA20

23.871

Buy

MA50

23.592

Buy

MA100

22.346

Buy

MA200

22.282

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Catalyst Pharmaceuticals Inc is 7.00, ranking 44 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 89.84%, representing a quarter-over-quarter decrease of 0.67%. The largest institutional shareholder is The Vanguard, holding a total of 8.41M shares, representing 6.84% of shares outstanding, with 1.53% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

15.95M

-2.09%

The Vanguard Group, Inc.

Star Investors

8.69M

-0.60%

State Street Investment Management (US)

6.41M

+16.92%

Deerfield Management Company, L.P.

4.97M

+72.77%

McEnany (Patrick James)

4.17M

-2.61%

Renaissance Technologies LLC

Star Investors

3.54M

+9.02%

Fundsmith LLP

3.36M

+24.17%

Geode Capital Management, L.L.C.

2.89M

+0.82%

American Century Investment Management, Inc.

2.53M

+43.81%

Dimensional Fund Advisors, L.P.

2.46M

+28.87%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Catalyst Pharmaceuticals Inc is 8.60, ranking 24 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.74. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Catalyst Pharmaceuticals Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.